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Abstract: An adenoviral vector (Ad) expressing a Wnt decoy receptor (sLRP6E1E2) is known to
induce an anti-fibrotic effect by inhibiting Wnt signaling. We evaluated its effects in vivo using pig
models and attempted to introduce an alginate gel-matrix system to prolong the effect of the Ad.
Transduction efficiency as to the biological activity of Ad in different forms was evaluated. Then,
50 days after the formation of full-thickness skin defects on the backs of Yorkshire pigs, scars were
treated with each form of Ad. Therapeutic efficacy and various factors influencing scar formation
and collagen rearrangement were analyzed. Inflammatory cell infiltration within the scar tissues was
also evaluated. Decoy Wnt receptor (sLRP6E1E2)-expressing adenovirus treatment improved scar
quality in a pig model. Loading this construct in alginate gel allows sustained virus release into local
tissues and prolongs Ad activity, thus maintaining its therapeutic effect longer in vivo.
Keywords: gene therapy; adenovirus; scar; alginate gel; decoy Wnt receptor; pig model
1. Introduction
Some wounds undergo an abnormal healing process and leave disfiguring scars. Hypertrophic
scars and keloids are representative examples of healed skin that are exceptionally red, thick, protruded,
and tight. Various mechanisms have been proposed to explain keloid pathogenesis, but the treatment
of keloids is extremely difficult as keloids frequently form at the site of injury, recur after excision, and
always overgrow beyond the boundaries of the original wound. This abnormal scarring is usually
the result of unbalanced collagen production and degradation. Chronic, persistent, and prolonged
proliferation of fibroblast leads to excessive synthesis and deposition of extracellular matrix (ECM)
components, especially collagen. Although patients usually suffer from aesthetic disturbances and
functional problems, these scars are difficult to treat due to their complex pathophysiology and
unknown polygenetic precipitating factors [1–3]. The response to treatment among patients is highly
variable, and currently available therapies often achieve only temporary improvement [1,4,5].
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Transforming growth factor-β (TGF-β) is a key regulator of fibroblast activation that drives the
excessive synthesis of ECM in fibrotic diseases. Recently, signaling cross-talk between the Wnt/β-catenin,
TGF-β1, and Smads was demonstrated, where Wnt/β-catenin signaling activates TGF-β19, 15 and
TGF-β1 promotes Wnt/β-catenin signaling. Therefore, inhibition of the canonical Wnt pathway can
be an effective approach to target TGF-β1 signaling, which can both synergistically downregulate
fibrogenesis. Therefore, on our previous research, we have demonstrated that soluble Wnt decoy
receptor of LRP6 (sLRP6E1E2)-expressing Ad (dE1-k35/sLRP6E1E2), which expresses LRP6’ E1 and E2
domains, prevents Wnt-mediated stabilization of cytoplasmic β-catenin, and decreases Wnt/β-catenin
signaling, and this construct can degrade extracellular matrix in HDFs, KFs, and primary keloid
spheroids, and thus it may be beneficial for the treatment of keloids [6].
Although adenoviral vectors are popular for gene therapy due to their high gene-transfer efficiency,
they can deteriorate rapidly within a few weeks due to a short half-life, enzymatic inactivation, and
transient effects. This may require repeated administration of an adenovirus to generate the desired
anti-fibrotic effect, and regional administration of a high concentration of Ad can impair potential
therapeutic effect and decrease safety. To deal with these problems, we loaded the virus in a sodium
alginate-based hydrogel, which is a natural polymer frequently used in biomedical applications [7–9].
Alginate gel can be used as a depot system for the sustained release of Ad and maintaining Ad viral
activity without affecting its biological activity [7,8]. Also, in previous research, we examined that the
use of alginate gel could increase the therapeutic efficacy of adenovirus in a pig scar model [10].
In this study, we investigate the anti-fibrotic and scar remodeling effect of decoy Wnt receptor
(sLRP6E1E2)-expressing adenovirus in vivo using a pig model. Additionally, we also demonstrate
the use of an alginate gel-matrix system as a delivery vehicle to entrap sLRP6E1E2-expressing Ad for
sustained release to promote scar tissue remodeling in a pig model.
2. Results
2.1. Ad Is Continuously Released from the Alginate Gel, and Gel Encapsulation Prolongs Ad Biological Activity
Transduction efficiency was compared by fluorescent micrographs showing SK-Hep1 cells
incubated with Ad in different forms (Figure 1). GFP (Green Fluorescent Protein) expression of naked
Ad was noticeably decreased from the 3rd day of incubation and almost absent after the 7th day
(Figure 1, upper row), whereas cells transduced with 5% gel-released Ad showed relatively strong and
sustained GFP expression until the 13th day (Figure 1, middle row). Also, GFP expression of Ad in
dissolved gel was prolonged and much higher than naked Ad (Figure 1, lower row). These results
demonstrate that the alginate gel provides a biocompatible environment for Ad to maintain its viral
activity and release Ad in a sustained manner.
Int. J. Mol. Sci. 2020, 21, 2242 3 of 12
Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 3 of 13 
 
 
Figure 1. Comparisons of GFP (Green Fluorescent Protein) expression level by fluorescent 
microscopies showing SK-Hep1 cells incubated with adenoviral vector (Ad) in various forms. Ad (1 
× 1010 viral particle of dE1/GFP) was encapsulated in 5% alginate gel and incubated with Dulbecco’s 
modified Eagle’s medium at 37 °C for 1, 3, 5, 7, 9, 11, and 13 days. SK-Hep1 cells transduced with 
dE1/GFP (naked Ad, top row), released Ad from 5% gel (middle row), and dissolved Ad-gel (lower 
row). GFP expression from naked Ad is strong at the beginning and dims after day 7, whereas from 
cells transduced with gel-release Ad accumulated amounts of released Ad gradually increased on day 
13 versus day 1. Additionally, GFP expression of Ad in dissolved gel was prolonged until day 13. 
These results demonstrates that Ad in alginate gel is released over time in a sustained manner. 
2.2. sLRP6E1E2-Expressing Ad/Gel Decreases scar Size and Color in Pig Scar Tissue. 
The therapeutic effect of sLRP6E1E2-expressing Ad on scar tissue was evaluated with scar size 
and erythema and melanin indices. The values listed below correspond to the following treatment 
groups: I, PBS (control); II, alginate gel (gel); III, alginate gel encapsulating dE1-k35/LacZ 
(gel+dE1−k35/LacZ; capsulated control); IV, naked dE1-k35/sLRP6E1E2 (naked LRP6); and V, 
alginate gel encapsulating naked dE1-k35/sLRP6E1E2 (gel+dE1−k35/sLRP6E1E2, capsulated LRP6). 
Photographs of scars were taken before and after each treatment, and the scar area was measured 
with Image J software (Figure 2a). The sizes of initial scars were measured as 1.46 ± 0.88, 1.51 ± 0.79, 
1.21 ± 0.15, 1.15 ± 0.18, and 1.42 ± 0.3 cm2 in each group, respectively, and there were no statistical 
differences. However, the sizes of the scars decreased to 79.8%, 71.3%, 71.9%, 70.1%, and 59.6% of 
initial scar, respectively, by the 50th day after treatments. This indicates that sLRP6E1E2 expression 
from Ad effectively reduced the size of the scar in Groups IV and V. Furthermore, in only Group V, 
gel encapsulating dE1-k35/sLRP6E1E2-treated scars showed a statistically significant reduction in 
scar area (p < 0.05; Figure 2b, left).  
Figure 1. Comparisons of GFP (Green Fluorescent Protein) expression level by fluorescent microscopies
showing SK-Hep1 cells incubated with adenoviral vector (Ad) in various forms. Ad (1 × 1010 viral
particle of dE1/GFP) was encapsulated in 5% alginate gel and incubated with Dulbecco’s modified
Eagle’s medium at 37 ◦C for 1, 3, 5, 7, 9, 11, and 13 days. SK-Hep1 cells transduced with dE1/GFP
(naked Ad, top row), released Ad from 5% gel (middle row), and dissolved Ad-gel (lower row).
GFP expression from naked Ad is strong at the beginning and dims after day 7, whereas from cells
transduced with gel-release Ad accumulated amounts of released Ad gradually increased on day 13
versus day 1. Additionally, GFP expression of Ad in issolved g l was prolonged until day 13. These
results demon trates that Ad in alginate el is rel a ed over tim in a sust ined manner.
2.2. sLRP6E1E2-Expressing Ad/Gel Decreases scar Size and Color in Pig Scar Tissue
The therapeutic effect of sLRP6E1E2-expressing Ad on scar tissue was evaluated with scar size and
erythema and melanin indices. The values listed below correspond to the following treatment groups:
I, PBS (control); II, algi ate gel (gel); III, al inate gel encapsulating dE1-k35/LacZ ( el+dE1-k35/LacZ;
capsulated control); IV, naked dE1-k35/sLRP6E1E2 (naked LRP6); and V, alginate gel encapsulating
naked dE1-k35/sLRP6E1E2 (gel+ E1-k35/sLRP6E1E2, capsulated LRP6). Photogra hs of scars were
taken before and after each treatment, and the scar ar was measured wit Image J soft are (Fig 2a).
The sizes of initial sc rs were me sured as 1.46 ± 0.88, 1.51 ± 0.79, 1.21 ± 0.15, 1.15 ± 0.18, and 1.42 ±
0.3 cm2 in each group, respectively, and there were no statistical differences. However, the sizes of the
scars decreased to 79.8%, 71.3%, 71.9%, 70.1%, and 59.6% of initial scar, respectively, by the 50th day
after treatments. This indicates that sLRP6E1E2 expression from Ad effectively reduced the size of the
scar in Groups IV and V. Furthermore, in only Group V, gel encapsulating dE1-k35/sLRP6E1E2-treated
scars showed a statistically significant reduction in scar area (p < 0.05; Figure 2b, left).
The erythema indices of the initial scars were 2.9 ± 0.54, 3.12 ± 0.91, 2.77 ± 0.5, 2.32 ± 0.19, and
3.02 ± 0.48 in each group, respectively. Compared to baseline, the erythema index was decreased to
91.6%, 88.2%, 87.4%, 85.2%, and 58.9% of the initial value in each group, respectively, by the 50th day
after treatments. The alginate gel encapsulating dE1-k35/sLRP6E1E2 treated scars (Group V) were
significantly improved in terms of erythema compared to other groups (p < 0.05; Figure 2b, middle).
Similarly, the melanin indices at 50 days were significantly reduced by 75.4%, 53.5%, 60.1%, 69.7%,
and 4.6% in each group, respectively, showing that sLRP6E1E2 expression from gel-encapsulated
Ad (Group V) reduces the melanin indices of scars (p < 0.05; Figure 2b, right). Taken together, these
results indicate that sLRP6E1E2-expressing Ad plays a prominent role in improving scar size and color.
Notably, Ad in an alginate gel-matrix system showed more effective biologic activities than naked Ad.
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Figure 2. Photographic analysis and therapeutic evaluation of scar area and color indices with Image 
J software and spectrophotometry. (a) The photographs of scars before and 50 days after treatment in 
pigs of each group (Groups: I, PBS (control); II, alginate gel (gel); III, alginate gel encapsulating dE1-
k35/LacZ (gel+dE1-k35/LacZ; capsulated control); IV, naked dE1-k35/sLRP6E1E2 (naked LRP6); and 
V, alginate gel encapsulating naked dE1-k35/sLRP6E1E2 (gel+dE1-k35/sLRP6E1E2, capsulated LRP6). 
(b) Therapeutic evaluation of the scars sLRP6E1E2-expressing Ad plays a prominent role in the 
reduction of scar surface area and color (mainly composed of erythema and melanin). Ad with 
alginate gel-matrix system showed more effective biologic activities than naked Ad. 
The erythema indices of the initial scars were 2.9 ± 0.54, 3.12 ± 0.91, 2.77 ± 0.5, 2.32 ± 0.19, and 
3.02 ± 0.48 in each group, respectively. Compared to baseline, the erythema index was decreased to 
91.6%, 88.2%, 87.4%, 85.2%, and 58.9% of the initial value in each group, respectively, by the 50th day 
after treatments. The alginate gel encapsulating dE1-k35/sLRP6E1E2 treated scars (Group V) were 
significantly improved in terms of erythema compared to other groups (p < 0.05; Figure 2b, middle). 
Similarly, the melanin indices at 50 days were significantly reduced by 75.4%, 53.5%, 60.1%, 69.7%, 
and 4.6% in each group, respectively, showing that sLRP6E1E2 expression from gel-encapsulated Ad 
(Group V) reduces the melanin indices of scars (p < 0.05; Figure 2b, right). Taken together, these 
results indicate that sLRP6E1E2-expressing Ad plays a prominent role in improving scar size and 
i . Photographic analy is and therapeutic evaluati n of scar area and color indices with Image
t are and spectroph tometry. (a) The photograph of scars before and 50 days after treatment
in pigs of each group (Groups: I, PBS (contro ); II, al inat gel (gel); III, alginate ge encapsulating
dE1-k35/LacZ (gel+dE1-k35/LacZ; capsula ed control); IV, naked dE1-k35/sLRP6E1E2 (naked LRP6);
and V, lginat gel encapsul ting naked dE1-k35/sLRP6E1 2 (gel+dE1-k35/sLRP6E1E2, capsulated
LRP6). (b) Therapeutic evaluation of the scars sLRP6E1E2-expressing Ad plays a prominent role in the
re ction of scar surface area and color (mainly composed of erythema and melanin). Ad with alginate
gel-matrix system showed more effective biologic activities than naked Ad.
2.3. sLRP6E1E2-Expressing Ad/Gel Remodels Scar by Inducing Collagen Rearrangement
Tissues were stained with picrosirius red, which specifically binds collagen fibrils of various
diameters. On the 50th day after treatment, scar tissues in Groups IV and V had closely packed collagen
fibers and formed complete bundles compared to Groups I to III, which is similar to normal dermal
structure (Figure 3). These data suggested that sLRP6E1E2 induces collagen rearrangement to resemble
that of mature, bundle-shaped collagen fibers, and gel encapsulation may enhance its efficacy.
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Figure 3. sLRP6E1E2-expressing Ad/gel induces collagen rearrangement. Picrosirius red staining in 
pig scar tissues. On the 50th day after treatment, premature collagen depositions were displaced by 
mature and well-arranged collagen bundles, and scar tissues in Groups IV and V had closely packed 
collagen fibers and formed complete bundles compared to other groups (Groups I to III), which is 
similar to normal dermal structure. Magnification × 100 (upper), × 400 (lower). 
2.4. sLRP6E1E2-Expressing Ad/Gel Reduces Collagen I, Elastin, and Fibronectin Expression. 
We examined the effects of sLRP6E1E2 overexpression on the major ECM components of scar 
tissues; type I collagen, elastin, and fibronectin. Immunohistochemical staining of scar sections 
revealed significant reductions in type I collagen and fibronectin in the alginate gel encapsulating 
dE1-k35/sLRP6E1E2-treated group (Group V) compared with other groups (** p < 0.01, Figure 4). 
Reductions of elastin in naked dE1-k35/sLRP6E1E2-treated scar tissues (Group IV) were significant 
compared to scars in Groups I, II, and III, but less than that of Group V.  
  
Figure 3. sLRP6E1E2-expre sing Ad/gel induces collagen rea rangement. Picrosirius red staining in
pig scar ti sues. On the 50th day after treatment, premature co lagen depositions were displaced by
mature and well-a ranged collagen bundles, and scar ti sues in Groups IV and V had closely packed
collagen fibers and formed complete bundles compared to other groups (Groups I to I), which is
similar to normal dermal structure. Magnification × 1 0 (u per), × 400 (lower).
2.4. sLRP6E1E2-Expressing Ad/Gel Reduces Collagen I, Elastin, and Fibronectin Expression
We examined the effects of sLRP6E1E2 overexpression on the major ECM components of scar
tissues; type I collagen, elastin, and fibronectin. Immunohistochemical staining of scar sections
revealed significant reductions in type I collagen and fibronectin in the alginate gel encapsulating
dE1-k35/sLRP6E1E2-treated group (Group V) compared with other groups (** p < 0.01, Figure 4).
Reductions of elastin in naked dE1-k35/sLRP6E1E2-treated scar tissues (Group IV) were significant
compared to scars in Groups I, II, and III, but less than that of Group V.




Figure 4. Representative sections of tissues from the center areas of the scar at 50th day after treatment 
were stained, and expression levels of type I collagen, elastin, and fibronectin were semi-
quantitatively analyzed with MetaMorph®. Values are calculated as the means of the optical density 
of six different digital images. The expression levels of type I collagen, elastin, and fibronectin were 
significantly reduced in the alginate gel encapsulating dE1-k35/sLRP6E1E2-treated group (Group V) 
compared with other groups. Reduction in type I collagen was significant in Group IV compared to 
Groups I to III, but significantly higher (220%) than that of Group V (* p < 0.05, ** p < 0.01). 
2.5. Alginate gel Encapsulating dE1-k35/sLRP6E1E2 Downregulates TGF-β1, Upregulates TGF-β3 mRNA 
Expression and Changes the Scar Remodeling Markers in Pig Scar Tissues  
To examine the mechanism by which sLRP6E1E2-expressing Ad suppresses expression of the 
major ECM components in pig scar tissues, the change of TGF-β1 and TGF-β3 mRNA expression 
levels were evaluated on various groups by qRT–PCR. The alginate gel encapsulating dE1-
k35/sLRP6E1E2-treated scar tissues (group V) showed decreased TGF-β1 mRNA expression (Figure 
5a) and increased TGF-β3 mRNA expression compared with other groups (Figure 5b). The TGF-β1 
mRNA level of scar tissues from Group V were 5- and 3-fold lower than that of Groups I and IV, 
respectively (p < 0.001). In addition, TGF-β3 mRNA levels of Group V were 1.6-fold higher compared 
to Group I and 1.8-fold higher compared to Group IV (p < 0.001). These results suggest that the 
reduced expression of ECM components by sLRP6E1E2 overexpression is associated with decreased 
TGF-β1 expression and increased TGF-β3 expression.  
Scar remodeling-associated molecules such as MMP-1, TIMP-1, and α-SMA are important 
markers of the effects of TGF-β on wound repair. We performed a qRT–PCR analysis of MMP-1, 
TIMP-1, and α-SMA and showed differential expression of these matrix remodeling-associated 
molecules among experimental groups. MMP-1 expression levels of Group V scar tissues were 
significantly increased by 4.9- and 1.7-fold, respectively, versus those of Groups I and IV scar tissues 
(p < 0.001, Figure 5c). In contrast, TIMP-1 and α-SMA expression levels of Group V scar tissues were 
significantly decreased by 2.2- and 2.8-fold, respectively, compared to Groups I and II (p < 0.01, Figure 
5d,e). However, there was no significant difference between Groups IV and V. These results suggest 
that sLRP6E1E2 upregulates MMP-1 and downregulates TIMP-1 and α-SMA, which are major 
players in collagen breakdown.  
Figure 4. Representative sections of tissues from the center areas of the scar at 50th day after treatment
were stained, and expression levels of type I collagen, elastin, and fibronectin were semi-quantitatively
analyzed with MetaMorph®. Values are calculated as the means of the optical density of six different
digital images. The expression levels of type I collagen, elastin, and fibronectin were significantly
reduced in the alginate gel encapsulating dE1-k35/sLRP6E1E2-treated group (Group V) compared with
other groups. Reduction in type I collagen was significant in Group IV compared to Groups I to III, but
significantly higher (220%) than that of Group V (* p < 0.05, ** p < 0.01).
2.5. Alginate gel Encapsulating dE1-k35/sLRP6E1E2 Downregulates TGF-β1, Upregulates TGF-β3 mRNA
Expression and Changes he Scar Remodeling Markers in Pi Scar Tissues
To examine the mechanism by which sLRP6E1E2-expressing Ad suppresses expression of the major
ECM components in pig scar tissues, the change of TGF-β1 and TGF-β3 mRNA expression levels were
evaluated on various grou s by qRT–PCR. T algi ate gel encapsulating dE1-k35/sLRP6E1E2-treated
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scar tissues (group V) showed decreased TGF-β1 mRNA expression (Figure 5a) and increased TGF-β3
mRNA expression compared with other groups (Figure 5b). The TGF-β1 mRNA level of scar tissues
from Group V were 5- and 3-fold lower than that of Groups I and IV, respectively (p < 0.001). In
addition, TGF-β3 mRNA levels of Group V were 1.6-fold higher compared to Group I and 1.8-fold
higher compared to Group IV (p < 0.001). These results suggest that the reduced expression of
ECM components by sLRP6E1E2 overexpression is associated with decreased TGF-β1 expression and





Figure 5. Alginate gel encapsulating dE1-k35/sLRP6E1E2 changes TGF-β mRNA expression and other 
scar remodeling markers in pig scar tissues. (a) TGF-β1 mRNA levels of Group V were 5-fold lower 
than that of Group I and 3-fold lower than that of Group IV scar tissues. (b) TGF-β3 mRNA levels of 
Group V were 1.6-fold higher than that of Group I scar tissues and 1.8-fold higher than that of Group 
IV scar tissues. (c) MMP-1 expression levels of Group V scar tissues were significantly increased by 
4.9- and 1.7-fold versus Groups I and IV scar tissues, respectively (*** p < 0.001). In contrast, TIMP-
1(d) and α-SMA expression (e) levels of Group V scar tissues were significantly decreased by 2.2- and 
2.8-fold versus Group I scar tissues, respectively (* p < 0.05, ** p < 0.01, *** p < 0.001). 
2.6. Alginate Gel Encapsulating dE1-k35/sLRP6E1E2 Decreases Inflammatory Cell Counts and Mast Cell 
Counts in Pig Scar Tissues  
To examine inflammatory cell infiltration within the scar tissues, the number of inflammatory 
cells was calculated from four serial H&E-stained tissue sections (Figure 6a). On day 5 of the 
postoperative period, the mean numbers of inflammatory cells within the scar tissue were 9.2 ± 2.39, 
9.25 ± 2.63, 5.80 ± 1.79, 7.75 ± 1.71, and 2.20 ± 1.30 in each group, respectively. On day 50 of the 
postoperative period, these were 9 ± 2.6, 8.5 ± 1.41, 8 ± 1.01, 6.28 ± 0.84, and 3.35 ± 0.30 in each group, 
respectively. The numbers of inflammatory cells on days 5 and 50 were significantly lower in the 
alginate gel encapsulating dE1-k35/sLRP6E1E2-treated scar tissues (Group V) (* p < 0.05; Figure 6 b,c). 
Mast cells are reported to be involved in the proliferation and contraction of fibroblasts, and the 
synthesis of ECM. They also play a key role in scar formation. On day 50 of the postoperative period, 
the mean numbers of mast cells were 10.17 ± 0.6, 8.97 ± 0.39, 8.53 ± 0.52, 7.03 ± 0.38, and 2.51 ± 0.25 in 
each group, respectively. A statistically significant decrease was seen in the mean number of mast 
cells in the alginate gel encapsulating dE1-k35/sLRP6E1E2-treated scar tissues (Group V) in 
comparison to other groups (* p < 0.05; Figure 6d). 
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Figure 5. Alginate gel encapsulating dE1-k35/sLRP6E1E2 changes TGF-β mRNA expression and other
scar remodelin markers in pi scar tissues. (a) TGF-β1 mRNA levels of Group V were 5-fold lower
than that of Group I and 3-fold lower than that of Group IV scar tissues. (b) TGF-β3 mRNA levels of
Group V were 1.6-fold higher than tha of Group I scar tissue and 1.8-fold higher than that of Group
IV scar tissues. (c) MMP-1 expression levels of Group V scar tissues wer signific ntly increased by
4.9- and 1.7-fold versus Groups I and IV scar tissues, respectively (*** p < 0.001). I contrast, TIMP-1
(d) and α-SMA expression (e) levels of Group V scar tissues were significantly decreased by 2.2- and
2.8-fold versus Group I scar tissues, respectively (* p < 0.05, ** p < 0.01, *** p < 0.001).
Scar remodeling-associated molecules such as MMP-1, TIMP-1, and α-SMA are important markers
of the effects of TGF-β on wound repair. We performed a qRT–PCR analysis of M P-1, TIMP-1, and
α-SMA and showed differential expression of these matrix remodeling-associated molecules among
experimental groups. MMP-1 expression levels of Group V scar tissu s were significantly inc eased by
4.9- and 1.7-fold, respectively, versus tho e of Groups I and IV scar tissues (p < 0.001, Figur 5c). In
contrast, TIMP-1 and α-SMA expressi n levels of Group V scar tissu s were ignificantly decreased by
2.2- and 2.8-fold, respectively, compared to Groups I and II (p < 0.01, Figure 5d,e). However, there was
no significant differenc between Groups IV and V. These results suggest that sLRP6E1E2 upregulates
MMP-1 and downregulates TIMP-1 and α-SMA, which are major players in collagen breakdown.
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2.6. Alginate Gel Encapsulating dE1-k35/sLRP6E1E2 Decreases Inflammatory Cell Counts and Mast Cell
Counts in Pig Scar Tissues
To examine inflammatory cell infiltration within the scar tissues, the number of inflammatory cells
was calculated from four serial H&E-stained tissue sections (Figure 6a). On day 5 of the postoperative
period, the mean numbers of inflammatory cells within the scar tissue were 9.2 ± 2.39, 9.25 ± 2.63,
5.80 ± 1.79, 7.75 ± 1.71, and 2.20 ± 1.30 in each group, respectively. On day 50 of the postoperative
period, these were 9 ± 2.6, 8.5 ± 1.41, 8 ± 1.01, 6.28 ± 0.84, and 3.35 ± 0.30 in each group, respectively.
The numbers of inflammatory cells on days 5 and 50 were significantly lower in the alginate gel
encapsulating dE1-k35/sLRP6E1E2-treated scar tissues (Group V) (* p < 0.05; Figure 6b,c).








Figure 6. Inflammatory cell and mast cell count in pig scar tissue. (a) Inflammatory cell (black arrow) 
infiltration, as demonstrated by H&E staining (magnification, 400×) and mast cell (white arrowhead) 
count with toluidine blue staining in the scar area. The numbers of inflammatory cells on day 5 (b) 
and day 50 (c) were significantly lower in the alginate gel encapsulating dE1-k35/sLRP6E1E2-treated 
scar tissues (Group V; * p < 0.05). (d) The numbers of mast cells on day 50 were significantly lower in 
the alginate gel encapsulating dE1-k35/sLRP6E1E2-treated scar tissues (Group V) compared with 
other groups (* p < 0.05). 
3. Discussion 
Keloids are benign fibroproliferative scars that invade surrounding normal skin beyond the 
original wound boundaries and keep growing slowly like a benign skin tumor [4]. The incidence has 
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(b) (d) (c) 
Figure 6. Inflammatory cell and mast cell count in pig scar tissue. (a) Inflammatory cell (black arrow)
infiltration, as demonstrated by H&E staining (magnification, 400×) and mast cell (white arrowhead)
count with toluidine blue staining in the scar area. The numbers of inflammatory cells on day 5 (b) and
day 50 (c) were significantly lower in the alginate gel encapsulating dE1-k35/sLRP6E1E2-treated scar
tissues (Group V; * p < 0.05). (d) The numbers of mast cells on day 50 were significantly lower in the
alginate gel encapsulating dE1-k35/sLRP6E1E2-treated scar tissues (Group V) compared with other
groups (* p < 0.05).
Mast cells are reported to be involved in the proliferation and contraction of fibroblasts, and the
synthesis of ECM. They also play a key role in scar formation. On day 50 of the postoperative period,
the mean numbers of mast cells were 10.17 ± 0.6, 8.97 ± 0.39, 8.53 ± 0.52, 7.03 ± 0.38, and 2.51 ± 0.25 in
each group, respectively. A statistically significant decrease was seen in the mean number of mast cells
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in the alginate gel encapsulating dE1-k35/sLRP6E1E2-treated scar tissues (Group V) in comparison to
other groups (* p < 0.05; Figure 6d).
3. Discussion
Keloids are benign fibroproliferative scars that invade surrounding normal skin beyond the
original wound boundaries and keep growing slowly like a benign skin tumor [4]. The incidence has
been reported at about 16% [11], and they are highly associated with dark, pigmented skin [12]. Unlike
hypertrophic scars, they rarely regress spontaneously, resulting in both aesthetic problems and pain
and functional disability.
Various mechanisms have been suggested to explain keloid pathogenesis: altered growth factor
regulation, immune dysfunction, aberrant collagen turnover, sebum or sebocytes as self-antigens,
altered mechanics, and altered apoptotic signaling in keloid fibroblasts [1,13]. Although a consistent
theory is still lacking, TGF-β1 is known as a potent fibrogenic growth factor that plays a primary
role in keloid pathophysiology [2,14,15]. Thus, targeting TGF-β1 with pharmacologic interventions
represents an attractive therapeutic option.
Skin injury involves the response of the Wnt/β-catenin pathway, with a critical role in epidermal
stem cell maintenance, hair follicle development, regeneration, and fibroblast-mediated scarring [16].
Activation of the Wnt pathway plays a profibrotic role in cutaneous wound healing. Wnt/β-catenin
signaling can upregulate TGF-β expression [17,18], and TGF-β1 can promoteβ-catenin signaling [19–21].
Furthermore, TGF-β stimulates canonical Wnt signaling by reducing the expression of the Wnt
antagonist Dickkopf protein-1 [22]. Prolonged activation of Wnt/β-catenin signaling has been observed
in human hyperplastic wounds [23]. Therefore, inhibition of the canonical Wnt pathway might be an
effective approach to target TGF-β signaling in fibrotic diseases such as keloids or hypertrophic scars.
We previously generated a novel soluble decoy Wnt receptor, sLRP6E1E2, which is composed of the
low-density lipoprotein receptor-related protein 6 (LRP6) E1 and E2 regions, for functional interaction
with Wnt and sLRP6E1E2-expressing replication-incompetent adenovirus (dE1-k35/sLRP6E1E2).
As LRP6 plays a key role in the activation of the canonical Wnt signaling pathway, these
replication-defective Ad-based vectors engineered with the soluble decoy Wnt receptor sLRP6E1E2
induce an anti-fibrotic effect by inhibiting Wnt and TGF-β signaling. The effect was observed in vitro
with human dermal fibroblasts and keloid spheroids in a previous study [6].
Using a pig scar model, we confirmed its therapeutic effect in vivo. Macroscopically, this approach
helps to decrease scar size and minimize discoloration. Microscopically, we observed that the collagen
structure of scar tissue became similar to normal tissue after treatment. Expression of structural
proteins was decreased in the treatment group. As with in vitro results, sLRP6E1E2-expressing
Ad downregulated TGF-β1 and upregulated TGF-β3 mRNA expression in vivo. In addition, the
expression of molecules that associated scar remodeling also convinced us of the anti-fibrotic effect
of sLRP6E1E2-expressing Ad. The expression level of MMP-1, which involves the breakdown of
extracellular matrix and tissue remodeling, breaking down the interstitial collagens, was increased
in the Ad-treated group. In contrast, TIMP-1, which has a role in extracellular matrix remodeling
by the inhibitory activity of MMP-1 [24,25], showed a decreased expression level as well as α-SMA
expression. The mast cells, known to be involved in the proliferation and contraction of fibroblasts, and
the synthesis of ECM, which play a key role in scar formation, are also observed in fewer numbers in
the virus-treated group. The numbers of inflammatory cells were lower in the sLRP6E1E2-expressing
Ad-treated group. Given that the keloid is the result of chronic inflammation of the reticula dermis [26],
this result is also expected to provide a positive basis for treating problem scarring in the future.
Although adenovirus is an attractive gene delivery vector with the advantages of high gene-transfer
ability, easy production/amplification, and low risk of insertional mutagenesis, its major drawback is
the rapid elimination of transduced cells [12]. As in vivo applications require long-term transduction,
we introduced an Ad/alginate gel depot system. Previous studies indicated that the biological activity
of Ad loaded in alginate gel is prolonged compared with that of naked Ad over an extended period of
Int. J. Mol. Sci. 2020, 21, 2242 9 of 12
time [7]. In addition, encapsulation of viral vectors may enhance the therapeutic effect by masking
viruses from clearance [9]. In this in vivo study, we confirm that alginate gel-encapsulated decoy Wnt
expressing Ad is more effective in scar management compared to naked Ad in a pig model. The alginate
gel reservoir releases Ad in a sustained manner and maintains the biological activity of Ad longer.
Alginate gel has also been shown to limit the Ad mobility by entrapping Ad within its scaffold, further
minimizing the spread of the replication-incompetent Ad outside the scar tissue. A microenvironment
surrounded with alginate gel also protects the virus from clearance by the innate immune system.
4. Materials and Methods
4.1. Preparation of Ad and Alginate Gel
A replication-incompetent Ad expressing the Wnt decoy receptor relaxin (dE1-k35/sLRP6E1E2)
and control Ad (dE1-k35/LacZ) [27] were used in this study. The propagation, purification, and
titration of Ad were performed as previously described [28,29]. An alginate (alginic acid sodium salt,
Sigma-Aldrich Co, St. Louis, MO, USA) solution of 5 wt % was prepared with 0.5 g alginate and 0.09 g
NaCl (Sigma) in 10 mL phosphate-buffered saline (PBS). The alginate solution was stirred for 24 h at
room temperature and gelated in 50 mM CaCl2 (Sigma) [7].
4.2. Biological Activity of Encapsulated Ad
To compare the biological activity of Ad in different forms, cellular transduction efficiency of
naked Ad, Ad released from the gel, and Ad trapped in gel were measured by GFP expression. Ad
(1 × 1010 viral particle of dE1/GFP) was encapsulated in 5% alginate gel and incubated with Dulbecco’s
modified Eagle’s medium at 37 ◦C. The media containing released Ad (2 mL) was collected at days 1,
3, 5, 7, 9, 11, and 13. The remaining Ad/alginate gel was dissolved with gel dissolution solution and
then 2 mL of cell culture media was added. SK-Hep 1 cells were then transduced with naked Ad,
released Ad from the gel, and gel-encapsulated Ad. At 72 h post-transduction, GFP-expressing cells
were identified by fluorescence microscopy (Olympus BX51; Olympus Optical, Tokyo, Japan).
4.3. Scar Formation
A female Yorkshire pigs (4 months of age, 40 kg) were used for the scar model. This animal study
was approved by an the Animal Care and Experiment Committee of Yonsei University (2013-0273, 8
October 2013). All animal experimental procedures were performed in accordance with the relevant
guidelines and regulations of the Department of Laboratory Animal Resources, Yonsei Biomedical
Research Institute, Yonsei University College of Medicine. Anesthesia was induced in each pig via
intramuscular injection of Zoletil® (5 mg/kg, Virbac, Carros, France) and Rompun® (2 mg/kg, Bayer,
Seoul, Korea) and maintained through inhalation of isoflurane (IsoFlo®, Abbott Laboratories, North
Chicago, Illinois, USA). After complete hair removal, 36 full-thickness skin defects (3 × 3 cm2) were
created symmetrically on the back of each Yorkshire pig, with 18 wounds on each side of the midline.
The wound was spaced at least 3 cm apart and reached the depth of the muscle fascia to mimic human
scar formation. Intravenous antibiotics were administered, and TegaDerm® (3M, St Paul, MN, USA)
was used as wound dressing for 5 days. Scar tissues, which were distinct in appearance compared to
the peripheral normal tissues, were formed 50 days after creating the initial skin defects.
4.4. Injection of Ad
Wound epithelialization and scar formation occurred on postoperative day 50. Scars were
divided into five treatment groups: (I), PBS (control, n = 7); (II), alginate gel (gel, n = 7); (III),
alginate gel encapsulating dE1-k35/LacZ (gel+dE1-k35/LacZ, capsulated control, n = 7); IV, naked
dE1-k35/sLRP6E1E2 (naked LRP6, n = 7); and V, alginate gel encapsulating naked dE1-k35/sLRP6E1E2
(gel+dE1-k35/sLRP6E1E2, capsulated LRP6, n = 8) (5 × 107 PFU). Under anesthesia, viruses were
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injected with a 27-gauge needle with a 1-mL syringe, and Ad/alginate gel mixtures were directly
injected into the intradermal layers of the scar regions.
4.5. Therapeutic Evaluation of Scar Size and Erythema and Melanin Indices
The surface areas of the scars were imaged with a digital camera. The images were measured with
a ruler and compared to a 1-cm2 standard, and measurements were assessed with ImageJ software
(National Institutes of Health, Bethesda, MD, USA). Scar color was quantitatively analyzed with a
spectrophotometer (CM-700D; Konica Minolta, Inc., Tokyo, Japan). The color of each scar was examined
with erythema (the degree of scar redness) and melanin (the degree of scar darkness) indices [30]. Each
value was measured at least three times, and the mean was calculated. All of the evaluations were
performed every 10 days until the 50th day after virus injection. We normalized the values of alginate
gel (gel), alginate gel encapsulating dE1-k35/LacZ (capsulated control), naked dE1-k35/sLRP6E1E2
(naked LRP6), and alginate gel encapsulating dE1-k35/sLRP6E1E2 (capsulated LRP6)-treated scars to
that of PBS-treated scars.
4.6. Histology and Immunohistochemistry
Representative sections collected 5 and 50 days after experiments were stained with Picrosirius
red (Sigma-Aldrich Co.) for evaluation of collagen-fiber arrangement with optical microscopy (BX51,
Olympus, Tokyo, Japan) at ×200 magnification. Immunohistochemistry was performed by the same
individual who was blinded to the experimental group and the tissue sections for analysis were
obtained from the center areas of scar tissue. Scar tissue sections were incubated at 4 ◦C overnight
with one of the following primary antibodies: mouse anti-collagen type-I (ab6308; Abcam, Ltd.,
Cambridge, UK), mouse anti-elastin (E4013; Sigma-Aldrich Co. St. Louis, MO, USA), and mouse
anti-fibronectin (sc-52331; Santa Cruz Biotechnology, Santa Cruz, USA). Then, tissues were incubated
at room temperature for 20 min with the DAKO Envision™ Kit (DAKO, Glostrup, Denmark) as a
secondary antibody. Diaminobenzidine/hydrogen peroxidase (DAKO) was used as the chromogen
substrate. All sections were counterstained with Meyer’s hematoxylin. Expression levels of type I
collagen, elastin, and fibronectin were semi-quantitatively analyzed with MetaMorph® image analysis
software (Molecular Devices, Sunnyvale, CA, USA). Values are calculated as the mean optical density
of six different digital images.
4.7. Real-Time Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR)
At 50 days after Ad injection, total RNA was prepared from tissue with TRIzol® reagent
(Invitrogen, Carlsbad, CA, USA), and complementary DNA was prepared from 500 ng total RNA
by Oligo dT (Bioneer Corp., Alameda, CA, USA) and a cDNA synthesis kit (Bioneer Corp.) under
the following conditions: 42 ◦C for 60 min, 94 ◦C for 5 min. Real-time PCR was performed with
a StepOnePlus™ Real-Time PCR System (Thermo Fisher Scientific, Waltham, MA, USA), following
a Taqman® Real-time PCR assay (Thermo Fisher Scientific; assay ID: Ss03382325_u1 (TGF-β1),
Ss03394349_g1 (TGF-β3), Ss04245657_g1 (matrix metalloproteinase-1, MMP-1), Ss03381944_u1 (tissue
inhibitor of metalloproteinase 1, TIMP-1), and Ss04245588_m1 (α-smooth muscle actin, α-SMA)).
Target mRNA expression levels were normalized to that of β-actin (Thermo Fisher Scientific; assay
ID: Ss03376563_uH) levels, and relative quantization was expressed as fold-induction compared with
control conditions in each tissue. PCR was performed three times for each mRNA in each tissue, and
the average value was calculated.
4.8. Statistics
Results are expressed as the mean ± standard deviation (SD). Data were analyzed with
repeated-measures one-way analysis of variance (ANOVA). Two sets of independent sample data were
compared using paired t-tests; p < 0.05 was considered statistically significant.
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5. Conclusions
Decoy Wnt receptor (sLRP6E1E2)-expressing adenovirus treatment improved scar quality in a
pig model. Loading this construct in alginate gel allows sustained virus release into local tissues and
prolongs Ad activity, thus maintaining its therapeutic effect longer in vivo. These advantages of the
Ad/alginate system could markedly augment the scar remodeling effects of sLRPE1E2 on scar tissue by
steadily providing a high concentration of Ad with minimal toxicity.
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